GrafixCORE®: Open-Label Study to Evaluate the Safety and Efficacy of GrafixCORE® for Complex Diabetic Foot Wounds

Inclusion Criteria: 1. Between 18 years and 85 years of age inclusive, as of the date of screening 2. Confirmed diagnosis of Type I or Type II Diabetes 3. Index wound graded in the Texas Classification System as Grade II-III, Stage A or C (without active infection) 4. Wound is located on the foot below the malleoli 5. Wound accommodates up to three (3) 5 cm x 5 cm pieces of GrafixCORE® that completely cover the wound 6. Patient's wound extends through the dermis and into subcutaneous tissue with evidence of exposed muscle, tendon, bone, and/or joint capsule 7. Patient has adequate circulation to the foot as documented by either: * Ankle Brachial Index (ABI) ≥ 0.5 and ≤ 1.2, or * In patients with non-compressible ankle vessels, a Toe BP ≥ 40 mmHg or TcPO2 \> 30 mmHg, or * Skin perfusion pressure \> 30 mmHg Exclusion Criteria: 1. Index Wound is of non-diabetic pathophysiology 2. Gangrene is present on any part of the affected foot 3. Index Wound is over a Charcot deformity 4. The longest dimension of the Index Wound exceeds 15 cm at the Baseline Visit 5. Patient has a glycated hemoglobin A1 (HbA1c) level of \>14% 6. Requiring intravenous (IV) antibiotics to treat the index wound infection at enrollment 7. Patient has a wound within 15cm of the Index Ulcer identified for study consideration 8. Patient is receiving oral or parenteral corticosteroids, immunosuppressive or cytotoxic agents 9. Patient is Human Immunodeficiency Virus (HIV) positive or has Acquired Immune Deficiency Syndrome (AIDS) 10. Current evidence of osteomyelitis, cellulitis, or other evidence of infection including fever or pus drainage from the wound site 11. Patient has active malignancy other than non-melanoma skin cancer 12. Patient's random blood sugar is \>450 mg/dl at screening 13. Patient has untreated alcohol or substance abuse at the time of screening, or is deemed to be non-adherent to the protocol by the Investigator 14. Pregnant women 15. Patient is currently enrolled or participated in another investigational device, drug, or biological trial within 30 days of screening 16. Patient has allergy to primary or secondary dressing materials used in this trial 17. Patient has had within the last 14 days, or is currently undergoing, or is planning for wound treatments with enzymes, growth factors, living skin, dermal substitutes or other advanced biological therapies 18. In the opinion of the Investigator, the patient is unsuitable for participation in the study